WO2005002504A3 - Protection against vertical transmission of pathogenic infections - Google Patents

Protection against vertical transmission of pathogenic infections Download PDF

Info

Publication number
WO2005002504A3
WO2005002504A3 PCT/US2004/015782 US2004015782W WO2005002504A3 WO 2005002504 A3 WO2005002504 A3 WO 2005002504A3 US 2004015782 W US2004015782 W US 2004015782W WO 2005002504 A3 WO2005002504 A3 WO 2005002504A3
Authority
WO
WIPO (PCT)
Prior art keywords
protection against
vertical transmission
against vertical
pathogenic infections
treatment
Prior art date
Application number
PCT/US2004/015782
Other languages
French (fr)
Other versions
WO2005002504A2 (en
Inventor
Gene M Shearer
Maria T Rugeles
Original Assignee
Us Gov Health & Human Serv
Gene M Shearer
Maria T Rugeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Gene M Shearer, Maria T Rugeles filed Critical Us Gov Health & Human Serv
Publication of WO2005002504A2 publication Critical patent/WO2005002504A2/en
Publication of WO2005002504A3 publication Critical patent/WO2005002504A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous

Abstract

Methods for treatment of pregnant women who are infected with HIV-1 and/or other infectious agents that are harmful to their fetuses and/or newborns are provided. In particular, treatment is accomplished by treating the pregnant women with recombinant ribonucleases (RNases) or by immunizing the woman with allogeneic leukocytes that stimulate the production of endogenous RNases that have viral inhibitory activity.
PCT/US2004/015782 2003-05-22 2004-05-19 Protection against vertical transmission of pathogenic infections WO2005002504A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47298303P 2003-05-22 2003-05-22
US60/472,983 2003-05-22

Publications (2)

Publication Number Publication Date
WO2005002504A2 WO2005002504A2 (en) 2005-01-13
WO2005002504A3 true WO2005002504A3 (en) 2005-09-01

Family

ID=33563722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015782 WO2005002504A2 (en) 2003-05-22 2004-05-19 Protection against vertical transmission of pathogenic infections

Country Status (1)

Country Link
WO (1) WO2005002504A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865224B2 (en) * 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DESROSIERS C.R. ET AL: "Prospects for an AIDS vaccine.", NATURE MEDICINE, vol. 10, no. 3, March 2004 (2004-03-01), pages 221 - 223, XP002988967 *
LUSCHER M.A. ET AL: "Anti-HLA alloantibody is found in children but does not correlat with a lack of HIV type I transmission from infected mothers.", AIDS RESEARCH AND HUMAN RETROVIRUSES., vol. 14, no. 2, January 1998 (1998-01-01), pages 99 - 107, XP008050392 *
LUSCHER M.A. ET AL: "Naturally occurring IgG anti alloantibody does not correlate wth HIV type I resisance in Nairobi prostitutes.", AIDS RESEARCH AND HUMAN RETROVIRUSES., vol. 14, no. 2, January 1998 (1998-01-01), pages 109 - 115, XP008050391 *
PANTALEO G. AND KOUP R.A. ET AL: "Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we schould know.", NATURE MEDICINE, vol. 10, no. 8, August 2004 (2004-08-01), pages 806 - 810, XP002988968 *
ROMANO G. ET AL: "Latest developments in gene transfer technology: Achievements perspectives and controversies over therapeutic applications.", STEM CELLS, vol. 18, January 2000 (2000-01-01), pages 19 - 39, XP002949601 *
ROSENBERG H.F. AND DOMCHOWSKEY B. ET AL: "Eosinophils, eosinophils ribonucleases, and their role in horst defence against respiratory virus pathogens.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 70, November 2001 (2001-11-01), pages 691 - 698, XP008050372 *
SHEARER G.M. ET AL: "Alloimmunization of immune-besed therapy and vaccine design against HIV/AIDS.", IMMUNOLOGY TODAY., vol. 20, no. 2, February 1999 (1999-02-01), pages 66 - 71, XP004157278 *
WANG Y. ET AL: "Allo-immunization elitics CD8+ cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women.", NATUTE MEDICINE, vol. 5, no. 9, September 1999 (1999-09-01), pages 1004 - 1009, XP000995119 *

Also Published As

Publication number Publication date
WO2005002504A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
MY144616A (en) Substituted dihydroquinazolines
WO2006072625A8 (en) Anti-kir combination treatments and methods
EP1381280A4 (en) Viral vectors and their use in therapeutic methods
WO2001064751A3 (en) High potency recombinant antibodies and method for producing them
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
ATE312510T1 (en) NUCLEIC ACIDS AND METHODS USING THEM TO FIGHT VIRAL PATHOGENS
HK1062029A1 (en) Multiplication of viruses in a cell culture
WO2000040273A3 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
TW200510449A (en) Acylated nonadepsipeptides
SE0300034D0 (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
HK1097467A1 (en) Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
EP2495252A3 (en) Soluble forms of hendra and nipah virus G glycoprotein
WO2003015708A8 (en) Composition and method for treating hiv infection
MXPA05009526A (en) Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection.
WO2005002504A3 (en) Protection against vertical transmission of pathogenic infections
MXPA02011969A (en) Methods of treating viral diseases with il-18 and il-18 combinations.
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
WO2003002528A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2003000274A3 (en) Bacteriophage preparation for the treatment of intracellular bacterial infection
AU6301398A (en) Arrestable therapeutic viral agent
MX2021010221A (en) Improved stem cell populations for allogeneic therapy.
AU2990300A (en) Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
Altura Why HDFx, a Stress Protein, May Ameliorate the Pig-Plague Effects of The African Swine Flu Virus (ASFV)
WO2023083906A3 (en) Pharmaceutical combinations for treatment of hbv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase